MAP's migraine drug Levadex hits all goals of first Phase III study
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals' inhaled acute migraine therapy candidate, Levadex (MAP0004), has met the four primary endpoints of relieving pain, nausea, and sensitivity to light and sound, in its first Phase III trial.